Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/207749
Title: Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry').
Author: Erton, Zeynep Belce
Sevim, Ecem
de Jesús, Guilherme Ramires
Cervera i Segura, Ricard, 1960-
Ji, Lan Lan
Pengo, Vittorio
Ugarte, Amaia
Andrade, Danieli
Andreoli, Laura
Atsumi, Tatsuya
Fortin, Paul R.
Gerosa, Maria
Zuo, Yu
Petri, Michelle
Sciascia, Savino
Tektonidou, Maria
Aguirre Zamorano, Mª. Ángeles
Branch, D Ware
Erkan, Doruk
Keywords: Embaràs
Mort del fetus
Avortament
Lupus eritematós
Síndrome antifosfolipídica
Assaigs clínics
Pregnancy
Fetal death
Abortion
Lupus erythematosus
Antiphospholipid syndrome
Clinical trials
Issue Date: 14-Jun-2022
Publisher: BMJ Publishing Group
Abstract: Objectives: To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. Methods: We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined 'aPL-related outcome' as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Results: Of the 55 first pregnancies observed after registry recruitment among nulliparous and multiparous participants, 15 (27%) resulted in early pregnancy loss <10 weeks gestation. Of the remaining 40 pregnancies: (1) 26 (65%) resulted in term live delivery (TLD), 4 (10%) in PTLD between 34.0 weeks and 36.6 weeks, 5 (12.5%) in PTLD before 34th week, and 5 (12.5%) in fetal death (two associated with genetic anomalies); and (2) The aPL-related composite outcome occurred in 9 (23%). One of 26 (4%) pregnancies with TLD, 3/4 (75%) with PTLD between 34.0 weeks and 36.6 weeks, and 3/5 (60%) with PTLD before 34th week were complicated with PEC, SGA and/or PI. Fifty of 55 (91%) pregnancies were in lupus anticoagulant positive subjects, as well as all pregnancies with aPL-related composite outcome. Conclusion: In our multicentre, international, aPL-positive cohort, of 55 first pregnancies observed prospectively, 15 (27%) were complicated by early pregnancy loss. Of the remaining 40 pregnancies, composite pregnancy morbidity was observed in 9 (23%) pregnancies.
Note: Reproducció del document publicat a: https://doi.org/10.1136/lupus-2021-000633
It is part of: Lupus Science & Medicine, 2022, vol. 9, num.1, e000633
URI: http://hdl.handle.net/2445/207749
Related resource: https://doi.org/10.1136/lupus-2021-000633
ISSN: 2053-8790
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
258010.pdf683.82 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons